| scholarly article | Q13442814 |
| P50 | author | Keith H. Nuechterlein | Q58888437 |
| P2093 | author name string | Jim Mintz | |
| Joseph Ventura | |||
| Kenneth L Subotnik | |||
| Michael J Gitlin | |||
| Gerhard S Hellemann | |||
| Stephen Marder | |||
| Indira R Singh | |||
| Leslie A Thornton | |||
| P2860 | cites work | One year outcome in first episode schizophrenia. Predictors of relapse | Q80358907 |
| Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors | Q80386974 | ||
| Using drug claims data to assess the relationship of medication adherence with hospitalization and costs | Q30652843 | ||
| Adherence to antipsychotic medications. | Q33766501 | ||
| Research diagnostic criteria: rationale and reliability | Q34711463 | ||
| Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia | Q35855167 | ||
| Defining and assessing adherence to oral antipsychotics: a review of the literature | Q36481418 | ||
| Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia | Q36665645 | ||
| Cost of relapse in schizophrenia | Q41008145 | ||
| Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder | Q43467235 | ||
| Electrodermal activity as a prodromal sign in schizophrenia | Q43704487 | ||
| Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment. | Q45996407 | ||
| Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting | Q46621896 | ||
| Supplementing supported employment with workplace skills training | Q46852012 | ||
| Baseline neurocognitive deficits in the CATIE schizophrenia trial. | Q50732363 | ||
| Expressed emotion, affective style, lithium compliance, and relapse in recent onset mania. | Q51214633 | ||
| Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. | Q51232311 | ||
| Major psychiatric disorders. A four-dimensional model. | Q51344799 | ||
| A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. | Q51990641 | ||
| Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. | Q52017906 | ||
| Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. | Q52068033 | ||
| Awareness of illness in schizophrenia and outpatient treatment adherence. | Q52891607 | ||
| Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. | Q53010881 | ||
| Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia | Q73395840 | ||
| Factors influencing compliance in schizophrenia patients | Q75183935 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| risperidone | Q412443 | ||
| P304 | page(s) | 286-292 | |
| P577 | publication date | 2011-01-04 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia | |
| P478 | volume | 168 |
| Q99604509 | A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach |
| Q100297411 | A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning |
| Q33879034 | Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers |
| Q38154852 | Alternative delivery systems for agents to treat acute agitation: progress to date |
| Q47133713 | Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia: Results from a prospective study |
| Q40621343 | Applications of temporal kernel canonical correlation analysis in adherence studies |
| Q92861680 | Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis |
| Q46497361 | Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness |
| Q95386203 | Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial |
| Q50660859 | Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. |
| Q48022142 | Community Health Workers: a Resource to Support Antipsychotic Medication Adherence |
| Q35607623 | Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment |
| Q35691666 | Do patterns of mental healthcare predict treatment failure in young people with schizophrenia? Evidence from an Italian population-based cohort study. |
| Q57484956 | Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness |
| Q92515332 | Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support |
| Q35186007 | Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia |
| Q37124948 | Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study |
| Q36211694 | Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? |
| Q90867967 | Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training |
| Q36445106 | Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model |
| Q47720713 | Experiencing antipsychotic discontinuation: results from a survey of Australian consumers |
| Q90421898 | Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning |
| Q50719241 | Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. |
| Q36597061 | Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia |
| Q37341552 | Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial |
| Q87262765 | Long-acting injectable antipsychotics: shall the last be first? |
| Q42149681 | Management of antipsychotic treatment discontinuation and interruptions using model-based simulations |
| Q38808583 | Medication adherence in patients with schizophrenia |
| Q35019929 | Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later |
| Q37981491 | Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments |
| Q38086645 | Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment |
| Q42288326 | Perceptions and knowledge of antipsychotics among mental health professionals and patients |
| Q35984960 | Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region |
| Q48151550 | Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses |
| Q35211161 | Remission and recovery during the first outpatient year of the early course of schizophrenia |
| Q90140425 | The Association Between Medication Adherence and Disease Stability in Patients with Severe Mental Disorders and Area Variation: Community-Based Prospective Study in Southwest China |
| Q45976253 | The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia. |
| Q64890047 | The clinician-patient working alliance: Is it a significant predictor of psychiatric medication adherence in a sample of recently released parolees? |
| Q34254832 | The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia |
| Q36169091 | Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia |
| Q38403164 | Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement |
| Q50765107 | Work functioning of schizophrenia patients in a rural south Indian community: status at 4-year follow-up. |
Search more.